Search Result

Results for "

STING activator

" in MedChemExpress (MCE) Product Catalog:

By Targets:	STING (91) 11β-HSD (2) Akt (4) AMPK (4) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (15) ATM/ATR (2) Autophagy (6) Bacterial (3) Bcl-2 Family (1) Biochemical Assay Reagents (1) Caspase (4) Cathepsin (1) CD28 (1) CXCR (4) Cyclic GMP-AMP Synthase (7) DNA/RNA Synthesis (6) Drug Derivative (1) EGFR (1) Endogenous Metabolite (5) Epoxide Hydrolase (1) ERK (2) Eukaryotic Initiation Factor (eIF) (1) Ferroptosis (3) FLAP (1) G-quadruplex (1) Glutathione Peroxidase (1) HBV (1) IFNAR (15) IKK (3) Influenza Virus (2) Integrin (1) Interleukin Related (9) Keap1-Nrf2 (3) Liposome (1) Mitochondrial Metabolism (1) Molecular Glues (1) mTOR (1) NF-κB (3) Opioid Receptor (1) p38 MAPK (2) PARP (5) PD-1/PD-L1 (5) PERK (1) Phosphatase (1) Phosphodiesterase (PDE) (4) PI3K (2) PROTACs (4) Reactive Oxygen Species (ROS) (7) Reference Standards (3) SARS-CoV (2) STAT (1) TNF Receptor (3) Topoisomerase (2) VEGFR (2)
By Research Areas:	Cancer (64) Infection (16) Inflammation/Immunology (51) Metabolic Disease (4) Neurological Disease (7)
Click Chemistry:	DBCO (1) Alkynes (1)
Oligonucleotides:	Cationic Lipids (1)

102

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Inhibitory Antibodies

Natural
Products

Click Chemistry

Oligonucleotides

Targets Recommended: STING

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10964

Vadimezan 70+ Cited Publications DMXAA; ASA-404	STING IFNAR Influenza Virus	Infection Cancer
Vadimezan (DMXAA), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities.

HY-112906

C-176 Maximum Cited Publications 110 Publications Verification	STING	Inflammation/Immunology
C-176 is a selective and blood-brain barrier permeable *STING* inhibitor. C-176 covalently targets transmembrane cysteine residue 91 and thereby blocking activation-induced palmitoylation of *STING* .

HY-12212

Omaveloxolone 20+ Cited Publications RTA 408	Keap1-Nrf2 STING Apoptosis	Inflammation/Immunology Cancer
Omaveloxolone (RTA 408) is an antioxidant inflammation modulator (AIM), which activates Nrf2 and suppresses nitric oxide (NO). Omaveloxolone attenuates osteoclastogenesis by inhibiting STING dependent NF-κb signaling.

HY-12512

cGAMP 25+ Cited Publications Cyclic GMP-AMP; 3',3'-cGAMP	STING	Inflammation/Immunology
cGAMP (Cyclic GMP-AMP) functions as an endogenous second messenger in metazoans and triggers interferon production in response to cytosolic DNA. cGAMP activates stimulator of interferon genes (STING), which activates a signaling cascade leading to the production of type I interferons and other immune mediators .

HY-13902

Berzosertib 20+ Cited Publications VE-822; VX-970; M6620	ATM/ATR Apoptosis STING Caspase	Infection Metabolic Disease Cancer
Berzosertib (VE-822) is an orally active, CNS-penetrant, and selective ATR kinase inhibitor. Berzosertib blocks ATR kinase activity, abrogates G₂/M cell cycle checkpoint, impairs DNA damage repair. Berzosertib induces apoptosis, inhibnits conlony migration, inhibits cell proliferation, and activates *cGAS-STING* axes in cancer cells. Berzosertib can be used for the research of cancers, such as head and neck squamous cell carcinoma, and colorectal cancer .

HY-12885A

2’3’-c-di-AM(PS)2 (Rp,Rp) disodium salt 85+ Cited Publications ADU-S100 disodium salt; MIW815 disodium salt; ML RR-S2 CDA disodium salt	STING	Inflammation/Immunology Cancer
2’3’-c-di-AM(PS)2 (Rp,Rp) disodium salt (ADU-S100 disodium salt) is an activator of stimulator of interferon genes (STING).

HY-12885

2’3’-c-di-AM(PS)2 (Rp,Rp) 85+ Cited Publications ADU-S100; MIW815; ML RR-S2 CDA	STING	Inflammation/Immunology Cancer
2’3’-c-di-AM(PS)2 (Rp,Rp) (ADU-S100), an activator of stimulator of interferon genes (STING), leads to potent and systemic tumor regression and immunity .

HY-12885B

2’3’-c-di-AM(PS)2 (Rp,Rp) ammonium salt 85+ Cited Publications ADU-S100 ammonium salt; MIW815 ammonium salt; ML RR-S2 CDA ammonium salt	STING	Inflammation/Immunology Cancer
2’3’-c-di-AM(PS)2 (Rp,Rp) ammonium salt (ADU-S100 ammonium salt), an activator of stimulator of interferon genes (STING), leads to potent and systemic tumor regression and immunity .

HY-145010

SN-011 10+ Cited Publications	STING	Inflammation/Immunology
SN-011 is a potent and selective mouse and human *STING* inhibitor, with an IC₅₀ of 76 nM for STING signaling. SN-011 competes with cyclic dinucleotide (CDN) for the binding pocket of the STING dimer, blocking CDN binding and STING activation. SN-011 can be used for the research of STING-driven autoimmune and inflammatory disease .

HY-12326A

c-di-AMP disodium 15+ Cited Publications Cyclic diadenylate disodium; Cyclic-di-AMP disodium	STING Bacterial Endogenous Metabolite	Inflammation/Immunology
c-di-AMP (Cyclic diadenylate) sodium is a *STING* agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP sodium is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP sodium acts as a potent mucosal adjuvant stimulating both humoral and cellular responses .

HY-10249

GSK-690693 40+ Cited Publications	Akt AMPK Autophagy	Cancer
GSK-690693 is an ATP-competitive pan-Akt inhibitor with IC₅₀s of 2 nM, 13 nM, 9 nM for Akt1, Akt2 and Akt3, respectively. GSK-690693 is also an AMPK inhibitor, affects Unc-51-like autophagy activating kinase 1 (ULK1) activity and robustly inhibits STING-dependent IRF3 activation .

HY-123963

C-178 5+ Cited Publications	STING	Inflammation/Immunology
C-178 is a potent and selective covalent inhibitor of *STING. C-178 binds to Cys91 and suppresses the STING* responses elicited by distinct bona fide activators in mouse but not human .

HY-148029

Dazostinag disodium TAK-676	STING	Cancer
Dazostinag disodium (TAK-676) is an agonist of *STING, triggering the activation* of STING signaling pathway and type I interferons. Dazostinag disodium is also a modulator of immune system, resulting complete regressions and durable memory T-cell immunity. Dazostinag disodium promotes durable IFN-dependent antitumor immunity .

HY-12326

c-di-AMP Cyclic diadenylate; Cyclic-di-AMP	STING Bacterial Endogenous Metabolite	Inflammation/Immunology
c-di-AMP (Cyclic diadenylate) is a *STING* agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP (Cyclic diadenylate) is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP (Cyclic diadenylate) acts as a potent mucosal adjuvant stimulating both humoral and cellular responses .

HY-147010

STING agonist-12 2 Publications Verification	STING	Inflammation/Immunology
STING agonist-12 (Compound 53) is a potent, orally active human *STING* activator with an EC₅₀ of 185 nM .

HY-164919

Calotatug ginistinag XMT-2056	Antibody-Drug Conjugates (ADCs) EGFR STING	Inflammation/Immunology Cancer
Calotatug ginistinag (XMT-2056) is an antibody-drug conjugate targeting HER2, with an effective payload connected via a linker (LP, HY-148067) to a *STING* agonist (STING agonist-20, HY-148068), and has potential immune activation and anticancer activity .

HY-110385

cGAMP disodium Maximum Cited Publications 26 Publications Verification Cyclic GMP-AMP disodium; 3',3'-cGAMP disodium	STING Endogenous Metabolite	Inflammation/Immunology
cGAMP (Cyclic GMP-AMP) disodium functions as an endogenous second messenger in metazoans and triggers interferon production in response to cytosolic DNA. cGAMP diammonium activates stimulator of interferon genes *(STING), which activates* a signaling cascade leading to the production of type I interferons and other immune mediators .

HY-116282B

Dextran sulfate sodium salt (MW 16000-24000) 2 Publications Verification DSS (MW 16000-24000); DXS (MW 16000-24000)	Biochemical Assay Reagents STING	Others
Dextran sulfate sodium salt (DSS) (MW 16000-24000) is a polymer of dehydrated glucose with a molecular weight of approximately 16000-24000. Dextran sulfate sodium salt with different molecular weights exhibits different biological activities. Dextran sulfate sodium salt (MW 16000-24000) induces *STING* polymerization and TBK1 activation .

HY-162874

diABZI-V/C-DBCO	STING IFNAR	Cancer
diABZI-V/C-DBCO is a *STING* agonist with an EC₅₀ of 1.47 nM. diABZI-V/C-DBCO activates the *STING* pathway, induces the production of IFN-I, and stimulates the secretion of IFN-β. diABZI-V/C-DBCO serves as a substrate for cathepsin B, and releases active diABZI-amine via cathepsin B-mediated cleavage. In an orthotopic mouse model of breast cancer, diABZI-V/C-DBCO increases serum IFN-β levels and the frequency of granzyme B ⁺ CD8 ⁺ T cells. diABZI-V/C-DBCO is applicable to research related to triple-negative breast cancer .

HY-168034

diABZI-4	STING Integrin NF-κB SARS-CoV	Infection Inflammation/Immunology
diABZI-4 is a *STING* activator and broad-spectrum antiviral agent with immunostimulatory activity. diABZI-4 triggers the TBK1-IRF3 and NF-κB signaling cascades by inducing STING oligomerization, thereby promoting the production of type I/III interferons and various proinflammatory cytokines. diABZI-4 exhibits broad-spectrum antiviral activity and effectively inhibits the replication of influenza A virus, SARS-CoV-2, herpes simplex virus, and other viruses. diABZI-4 also activates lymphocytes and macrophages to provide significant pre- and post-exposure protection in viral disease models. diABZI-4 can be used to study COVID-19, respiratory viral infections, and related immunopathological mechanisms .

HY-152955

STING agonist-22 1 Publications Verification	STING	Infection Inflammation/Immunology
STING agonist-22 (CF501) is a potent non-nucleotide *STING* agonist. STING agonist-22 is a adjuvant by activating STING to induce the type I interferon (IFN-I) response and proinflammatory cytokine production. STING agonist-22 can be used as an adjuvant to boost the original protein vaccine, producing potent, broad, and long-term immune protection. STING agonist-22 can be used for SARS-CoV-2 variants and sarbecovirus diseases research .

HY-128481

SB24011	STING	Inflammation/Immunology Cancer
SB24011 is a *STING* modulator and a *TRIM29-STING* protein-protein interaction inhibitor. SB24011 blocks TRIM29-induced K48-linked specific ubiquitination by binding to *STING, thereby upregulating intracellular STING* protein levels. SB24011 enhances inflammatory cytokine expression and STING-mediated immune responses, and exhibits abscopal antitumor activity that promotes tumor regression and activates T cell infiltration. When combined with STING agonists or anti-PD1 antibodies, SB24011 synergistically enhances antitumor responses. SB24011 is suitable for research related to colon cancer and melanoma .

HY-148488

A18-Iso5-2DC18	Liposome STING	Inflammation/Immunology Cancer
A18-Iso5-2DC18 (Compound A18) is a cyclic lipidoid. A18-Iso5-2DC18 partially activates *STING*. A18-Iso5-2DC18 promotes mRNA protein expression and induces a strong immune response. A18-Iso5-2DC18 can be used in melanoma research .

HY-N0660

Jujuboside B	Apoptosis PARP Caspase AMPK Autophagy VEGFR Keap1-Nrf2 STING 11β-HSD Ferroptosis PI3K Akt p38 MAPK ERK	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the *Nrf2-STING* signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM_2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes .

HY-138683

STING-IN-3 2 Publications Verification	STING	Inflammation/Immunology
STING-IN-3 is an inhibitor of stimulator of interferon genes (STING). STING-IN-3 efficiently inhibits both hsSTING and mmSTING through covalently target the predicted transmembrane cysteine residue 91 and thereby block the activation-induced palmitoylation of STING .

HY-177338

STING agonist-45	STING Cyclic GMP-AMP Synthase IFNAR TNF Receptor Interleukin Related	Inflammation/Immunology Cancer
STING agonist-45 is a selective *STING* agonist (EC₅₀ = 0.28 μM). STING agonist-45 activates the innate immune response through the *cGAS-STING* pathway, upregulating key markers such as p-TBK1 and IRF3. STING agonist-45 exhibits robust *STING* activation in human peripheral blood mononuclear cells (PBMCs), inducing the production of type I interferons (such as IFN-β) and downstream cytokines (such as TNF-α and IL-6). STING agonist-45 enhances anti-tumor immunity, inhibits tumor growth, and increases CD8 ⁺ T cell infiltration in mouse models. STING agonist-45 is promising for the study of *STING*-related diseases .

HY-164278

diABZI-V/C-Mal	STING Cathepsin	Cancer
diABZI-V/C-Mal is a *STING* agonist (with a *STING* EC₅₀ of 314 nM in TH1 dual reporter cells) and a Cathepsin B substrate. diABZI-V/C-Mal activates *STING, thereby triggering the IRF3* signaling pathway. diABZI-V/C-Mal is cleaved by Cathepsin B to regenerate diABZI-NH₂ .

HY-157214

NVS-STG2 1 Publications Verification	STING Molecular Glues	Cancer
NVS-STG2 is a molecular glue that targets *STINGactivates STING-mediated immune signaling. NVS-STG2 induces higher-order oligomerization of human STING* by binding to pockets between adjacent STING dimer transmembrane domains, effectively acting as a molecular glue. NVS-STGI enhances the activity of cGAMP by inducing the formation of more abundant and larger oligomers. NVS-STG2 produces antitumor activity in animal models .

HY-151970

STING-IN-4	STING	Inflammation/Immunology
STING-IN-4 (Compound 1) is a *STING* inhibitor that inhibits STING expression and hence reducing activation of STING and nuclear factor-κB (NF-κB) signaling. STING-IN-4 shows anti-inflammatory activity and can be used for the research of sepsis .

HY-158045

PROTAC PARP1 degrader-1	PROTACs PARP	Cancer
PROTAC PARP1 degrader-1 is a PARP1 PROTAC degrader with a DC₅₀ value of 252.5 nM. PROTAC PARP1 degrader-1, combined with Daunorubicin (HY-13062A), induces the accumulation of cytoplasmic DNA fragments, activates the *cGAS/STING* innate immune pathway, and remodels the tumor microenvironment. PROTAC PARP1 degrader-1 can be used in research related to breast cancer .

HY-164288

TDI-6570 TDI-006570	Cyclic GMP-AMP Synthase STING	Neurological Disease Inflammation/Immunology
TDI-6570 (TDI-006570) is a blood-brain barrier-permeable, orally active cGAS inhibitor with an IC₅₀ of 1.64 μM. TDI-6570 exhibits high gastrointestinal absorption and a long brain half-life in mice, and shows no toxicity to primary neurons. By inhibiting the *cGAS-STING-IFN* signaling pathway, TDI-6570 reduces *STING* levels and the activation of TBK1, blocks double-stranded DNA-induced cGAS activation and downstream interferon-stimulated gene expression, thereby reducing tau protein spread and improving synaptic loss. TDI-6570 reverses memory deficits, increases the amplitude of long-term potentiation, enhances the MEF2C transcriptional network, restores PSD-95 and vGAT punctate structures, and significantly improves cognitive resilience. TDI-6570 can be applied to the research of Alzheimer's disease, Parkinson's disease, systemic lupus erythematosus, as well as various central nervous system and autoimmune diseases .

HY-152959

STING agonist-26	STING	Infection Cancer
STING agonist-26 (CF508) is a non-nucleotide small-molecule *STING* agonist. STING agonist-23 activates STING, increases phosphorylation of *STING, TBK1* and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains .

HY-12326B

c-di-AMP diammonium 15+ Cited Publications Cyclic diadenylate diammonium; Cyclic-di-AMP diammonium	STING Bacterial Endogenous Metabolite	Inflammation/Immunology
c-di-AMP diammonium is a *STING* agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP diammonium is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP diammonium acts as a potent mucosal adjuvant stimulating both humoral and cellular responses .

HY-12885C

2’3’-c-di-AM(PS)2 (Rp,Rp) enantiomer ammonium salt ADU-S100 enantiomer ammonium salt; MIW815 enantiomer ammonium salt; ML RR-S2 CDA enantiomer ammonium salt	IFNAR	Inflammation/Immunology
2’3’-c-di-AM(PS)2 (Rp,Rp) enantiomer ammonium salt (ADU-S100 enantiomer ammonium salt) is the less active enantiomer of 2’3’-c-di-AM(PS)2 (Rp,Rp). 2’3’-c-di-AM(PS)2 (Rp,Rp) is an activator of stimulator of interferon genes (STING) .

HY-139179

STING agonist-14	STING	Infection Cancer
STING agonist-14 (compound 12b) is a potent *STING* agonist that is efficacious across species. STING agonist-14 could activate the pathway by directly binding human STING. STING agonist-14 can be used for the research of tumours or viral infections .

HY-152956

STING agonist-23	STING	Infection Cancer
STING agonist-23 (CF502) is a non-nucleotide small-molecule *STING* agonist. STING agonist-23 activates STING, increases phosphorylation of *STING, TBK1* and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains .

HY-175714

STING agonist-46	STING	Inflammation/Immunology Cancer
STING agonist-46 is an orally active STING agonist. STING agonist-46 activates the STING signaling pathway, promoting phosphorylation of TBK1 and IRF3, and secretion of IFN-β and IP-10. STING agonist-46 directly binds to STING and increases its thermal stability. STING agonist-46 demonstrates potent anti-tumor efficacy in B16F10, CT26, and 4T1 mouse models. STING agonist-46 can be used for cancer immunotherapy studies .

HY-162133

MSA-2-Pt	STING Apoptosis IKK IFNAR NF-κB	Cancer
MSA-2-Pt, platinum salt-modified MSA-2 (HY-136927), is a *STING* agonist. MSA-2-Pt inducing cell death by platinum and activating the STING pathway by MSA-2. MSA-2-Pt direct activates STING pathway, induces phosphorylation of TBK1, IRF3, and NF-κB p65. MSA-2-Pt enhances tumor infiltration of CD4 ⁺ and CD8 ⁺ T cells, and induces tumor cell death and apoptosis in mouse colon carcinoma and melanoma models .

HY-175167

diABZI-i	STING IFNAR	Inflammation/Immunology
diABZI-i is an orthogonal *STING* inhibitor. diABZI-i significantly inhibits cGAMP-induced IFNβ in PBMCs. diABZI-i also activates constitutive signaling of V155M SAVI and exerts potent agonistic effects in the STING V155M THP-1 cell model. diABZI-i can be used for research on monogenic autoinflammatory diseases such as SAVI .

HY-138646

Poly(deoxyadenylic-thymidylic) acid sodium 4 Publications Verification Poly(dA:dT) sodium	Cyclic GMP-AMP Synthase STING	Inflammation/Immunology
Poly(deoxyadenylic-thymidylic) acid (Poly(dA:dT)) sodium is a double-stranded DNA stimulant. Poly(deoxyadenylic-thymidylic) acid sodium is recognized by the intracellular DNA sensor DDX41 and activates the innate immune pathway via the adaptor protein *STING*, inducing the production of cytokines such as type I interferons. Poly(deoxyadenylic-thymidylic) acid sodium also serves as an in vitro transcription template for free RNA polymerase .

HY-144329

STING agonist-11	STING	Inflammation/Immunology Cancer
STING agonist-11 (Compound 92) is a potent small molecule cyclic urea activator of *STING* with EC₅₀ of 18 nM. Activation of STING is a highly promising approach in immunotherapy .

HY-148606

STING modulator-3	STING	Cancer
STING modulator-3 is a *STING* inhibitor. STING modulator-3 inhibits R232 STING with an K_i value of 43.1 nM in scintillation proximity assay. STING modulator-3 has no effect on IRF-3 activation or TNF-β induction in THP-1 cells .

HY-174136

STING Degrader-2	STING IFNAR	Inflammation/Immunology
STING Degrader-2 is an orally active *STING* degrader that promotes proteasome-independent degradation of STING. STING Degrader-2 inhibits cGAMP-induced STING activation, suppresses STING oligomerization, and inhibits phosphorylation of STING and interferon regulatory factor 3 (IRF3). STING Degrader-2 reduces serum IFN-β and CXCL-10 levels in a cGAMP-induced autoimmune disease mouse model. STING Degrader-2 can be used for the research of autoimmune diseases .

HY-110385A

cGAMP diammonium Maximum Cited Publications 26 Publications Verification Cyclic GMP-AMP diammonium; 3',3'-cGAMP diammonium	STING Endogenous Metabolite	Inflammation/Immunology
cGAMP (Cyclic GMP-AMP) diammonium functions as an endogenous second messenger in metazoans and triggers interferon production in response to cytosolic DNA. cGAMP diammonium activates stimulator of interferon genes *(STING), which activates* a signaling cascade leading to the production of type I interferons and other immune mediators .

HY-10964R

Vadimezan (Standard) DMXAA (Standard); ASA-404 (Standard)	STING IFNAR Influenza Virus Reference Standards	Infection Cancer
Vadimezan (Standard) (DMXAA (Standard)) is the analytical standard of Vadimezan (HY-10964). This product is intended for research and analytical applications. Vadimezan (DMXAA; ASA-404), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities.

HY-139678

SC13	FLAP Opioid Receptor Apoptosis STING	Neurological Disease Cancer
SC13 is an orally active, selective Flap structure-specific endonuclease 1 (FEN1) inhibitor and mu opioid receptor (MOR) activator. SC13 impairs DNA damage repair and induces apoptosis in cancer cells. SC13 activates *cGAS-STING* signaling, increases chemokine secretion, and promotes CAR-T cell infiltration at solid tumour sites. SC13 can be used for the research of solid tumours and pain .

HY-175478

Enpp-1-IN-27	Phosphodiesterase (PDE) STING	Inflammation/Immunology Cancer
Enpp-1-IN-27 is a selective ENPP1 inhibitor with an IC₅₀ of 14.68 nM, exhibiting approximately 410-fold selectivity against ENPP2 and 10-fold selectivity against ENPP3. Enpp-1-IN-27 stabilizes cGAMP levels and activates the *STING* pathway, promoting cytokine release and enhancing innate immune responses. Enpp-1-IN-27 induces ISRE activation and amplified cGAMP-mediated immune responses and shows the desired antitumor efficacy in the 4T1 and CT26 syngeneic mouse models. Enpp-1-IN-27 can used for the studies of breast cancer and colon cancer .

HY-143321

STING agonist-13	STING	Cancer
STING agonist-13 is a stimulator of interferon genes (STING) agonist, for cancer immunity via STING-mediated immune activation. STING agonist-13 can stimulate *STING* downstream signaling and promoting type I interferon immune responses. STING agonist-13 significantly decreases tumor volume and shows immunological memory-derived cancer inhibition .

HY-175210

STING-IN-16	STING Interleukin Related IFNAR Reactive Oxygen Species (ROS) Apoptosis	Inflammation/Immunology
STING-IN-16 is a *STING* inhibitor with IC₅₀ values of 44 nM (human) and 32 nM (mice) for cellular *STING* inhibition. STING-IN-16 effectively inhibits the activation of the *STING* axis in both human and murine cells. STING-IN-16 can restore renal mitochondrial function, suppress reactive oxygen species (ROS) production, and reduce cell apoptosis. STING-IN-16 shows robust anti-inflammatory efiicacy in vivo. STING-IN-16 can be used for the study of autoimmune and autoinflammatory diseases .

HY-152961

STING agonist-28	STING	Infection
STING agonist-28 (CF510) is a non-nucleotide small-molecule *STING* agonist. STING agonist-23 activates STING, increases phosphorylation of *STING, TBK1* and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains .

Cat. No.	Product Name

HY-L031

Small Molecule Immuno-Oncology Compound Library

783 compounds

Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.

MCE Small Molecule Immuno-Oncology Compound Library offers 783 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Cat. No.	Product Name	Target	Research Area	Image

HY-P990181

Anti-Mouse myeloperoxidase/MPO Antibody (6G4) 1 Publications Verification	Glutathione Peroxidase STING	Inflammation/Immunology
Anti-Mouse myeloperoxidase/MPO Antibody (6G4) is an anti-mouse myeloperoxidase/MPO IgG2c monoclonal antibody. Anti-Mouse myeloperoxidase/MPO Antibody (6G4) can activate the cGAS/STING pathway. Anti-Mouse myeloperoxidase/MPO Antibody (6G4) induces acute and chronic kidney injury in mice. Anti-Mouse myeloperoxidase/MPO Antibody (6G4) is often used in the construction of inflammation conditions models such as anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) .

Cat. No.	Product Name	Category	Target	Chemical Structure